The Pharmacogenomics Journal
ISSN 1470-269x · Springer Nature · United Kingdom · active 1988–2026
Metrics
“Cites per paper” is a two-year cited-by rate computed from OpenAlex. It is not a Clarivate Journal Impact Factor — we neither compute nor license that metric. Citation rates differ enormously between fields, so compare within a discipline.
Indexing & access
Access status: unknown. Where this comes from publisher-level signals rather than works-level data it is a heuristic — confirm on the journal’s own site, especially regarding any article processing charge.
Scope
Frequently asked
Is The Pharmacogenomics Journal a predatory journal?
Our screening does not flag The Pharmacogenomics Journal. That is not a guarantee of quality — it means the venue is not on Beall's archive (frozen since 2017) and does not match our name-pattern heuristic. It is listed in Scopus, Web of Science, PubMed, which is a positive signal.
Is The Pharmacogenomics Journal indexed in Scopus or Web of Science?
Per our venue index, The Pharmacogenomics Journal appears in: Scopus, Web of Science, PubMed. Index membership changes over time — confirm on the index's own site before relying on it.
What is The Pharmacogenomics Journal's impact?
Papers in The Pharmacogenomics Journal are cited about 3.2 times each within two years of publication, and Scimago places it in Q2, with an h-index of 109. This is not a Clarivate Journal Impact Factor — we neither compute nor license that metric — and a citation rate is a property of a field as much as of a journal.
Is The Pharmacogenomics Journal open access?
We hold no reliable open-access classification for The Pharmacogenomics Journal. Check the journal's own site for its access model and any article processing charge.
Similar venues
- Molecular Diagnosis & TherapyQ1 · Adis, Springer Healthcare
- Chemico-Biological InteractionsQ1 · Elsevier BV
- Biochemical PharmacologyQ1 · Elsevier BV
- Journal of Personalized MedicineQ1 · Multidisciplinary Digital Publishing Institute
- Clinical and Translational ScienceQ1 · Wiley
- Expert Opinion on Drug Metabolism & ToxicologyQ1 · Taylor & Francis